Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention

Paul W. Armstrong, Peter X. Adams, Hussein R. Al-Khalidi, Christian Hamm, David Holmes, William O'Neill, Thomas G. Todaro, Alec Vahanian, Frans Van De Werf, Christopher B. Granger

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The APEX-AMI study represents a major academic/industrial collaboration aimed at recruiting the largest PCI STEMI population ever enrolled in a randomized clinical trial to assess the efficacy of pexelizumab at day-90 mortality. The trial is designed to be innovative, efficient in operations, and performed in the context of routine care. Because it targets a high-risk STEMI population the results will be most informative to clinical practice. A major international collaborative effort is now underway to recruit the targeted population of 8500 patients so as to provide a reliable assessment of the ultimate role of the inflammatory mediator pexelizumab in management of acute MI. The first patient was randomized on July 13, 2004. Study enrollment from 17 countries and more than 300 sites is expected to unfold over the subsequent 2.5 years.

Original languageEnglish (US)
Pages (from-to)402-407
Number of pages6
JournalAmerican Heart Journal
Volume149
Issue number3
DOIs
StatePublished - Jan 1 2005

Fingerprint

Percutaneous Coronary Intervention
Myocardial Infarction
Placebos
Population
Randomized Controlled Trials
Mortality
pexelizumab
ST Elevation Myocardial Infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) : A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. / Armstrong, Paul W.; Adams, Peter X.; Al-Khalidi, Hussein R.; Hamm, Christian; Holmes, David; O'Neill, William; Todaro, Thomas G.; Vahanian, Alec; Van De Werf, Frans; Granger, Christopher B.

In: American Heart Journal, Vol. 149, No. 3, 01.01.2005, p. 402-407.

Research output: Contribution to journalArticle

Armstrong, Paul W. ; Adams, Peter X. ; Al-Khalidi, Hussein R. ; Hamm, Christian ; Holmes, David ; O'Neill, William ; Todaro, Thomas G. ; Vahanian, Alec ; Van De Werf, Frans ; Granger, Christopher B. / Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) : A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. In: American Heart Journal. 2005 ; Vol. 149, No. 3. pp. 402-407.
@article{b15e229b95354fdeaf073a39aecd7f10,
title = "Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention",
abstract = "The APEX-AMI study represents a major academic/industrial collaboration aimed at recruiting the largest PCI STEMI population ever enrolled in a randomized clinical trial to assess the efficacy of pexelizumab at day-90 mortality. The trial is designed to be innovative, efficient in operations, and performed in the context of routine care. Because it targets a high-risk STEMI population the results will be most informative to clinical practice. A major international collaborative effort is now underway to recruit the targeted population of 8500 patients so as to provide a reliable assessment of the ultimate role of the inflammatory mediator pexelizumab in management of acute MI. The first patient was randomized on July 13, 2004. Study enrollment from 17 countries and more than 300 sites is expected to unfold over the subsequent 2.5 years.",
author = "Armstrong, {Paul W.} and Adams, {Peter X.} and Al-Khalidi, {Hussein R.} and Christian Hamm and David Holmes and William O'Neill and Todaro, {Thomas G.} and Alec Vahanian and {Van De Werf}, Frans and Granger, {Christopher B.}",
year = "2005",
month = "1",
day = "1",
doi = "10.1016/j.ahj.2004.12.015",
language = "English (US)",
volume = "149",
pages = "402--407",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI)

T2 - A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention

AU - Armstrong, Paul W.

AU - Adams, Peter X.

AU - Al-Khalidi, Hussein R.

AU - Hamm, Christian

AU - Holmes, David

AU - O'Neill, William

AU - Todaro, Thomas G.

AU - Vahanian, Alec

AU - Van De Werf, Frans

AU - Granger, Christopher B.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - The APEX-AMI study represents a major academic/industrial collaboration aimed at recruiting the largest PCI STEMI population ever enrolled in a randomized clinical trial to assess the efficacy of pexelizumab at day-90 mortality. The trial is designed to be innovative, efficient in operations, and performed in the context of routine care. Because it targets a high-risk STEMI population the results will be most informative to clinical practice. A major international collaborative effort is now underway to recruit the targeted population of 8500 patients so as to provide a reliable assessment of the ultimate role of the inflammatory mediator pexelizumab in management of acute MI. The first patient was randomized on July 13, 2004. Study enrollment from 17 countries and more than 300 sites is expected to unfold over the subsequent 2.5 years.

AB - The APEX-AMI study represents a major academic/industrial collaboration aimed at recruiting the largest PCI STEMI population ever enrolled in a randomized clinical trial to assess the efficacy of pexelizumab at day-90 mortality. The trial is designed to be innovative, efficient in operations, and performed in the context of routine care. Because it targets a high-risk STEMI population the results will be most informative to clinical practice. A major international collaborative effort is now underway to recruit the targeted population of 8500 patients so as to provide a reliable assessment of the ultimate role of the inflammatory mediator pexelizumab in management of acute MI. The first patient was randomized on July 13, 2004. Study enrollment from 17 countries and more than 300 sites is expected to unfold over the subsequent 2.5 years.

UR - http://www.scopus.com/inward/record.url?scp=17844391259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844391259&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2004.12.015

DO - 10.1016/j.ahj.2004.12.015

M3 - Article

C2 - 15864228

AN - SCOPUS:17844391259

VL - 149

SP - 402

EP - 407

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 3

ER -